What Is SARCLISA®?
SARCLISA® is indicated:1
- in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
- in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
Why Consider SARCLISA® for Your Patients?
SARCLISA® in combination with carfilzomib and dexamethasone can be used to treat patients with multiple myeloma who have received 1 to 3 prior lines of therapy.1
SARCLISA® is the first anti-CD38 antibody treatment indicated in combination with pomalidomide and dexamethasone available in Canada for relapsed and refractory multiple myeloma.1,2
SARCLISA® offers patients who have undergone therapy for multiple myeloma with a potential treatment option.1
The REACH™ Patient Support Program
Sanofi Canada has developed the REACH™ Patient Support Program for patients who have recently been prescribed SARCLISA® for relapsed and/or refractory multiple myeloma.1
Learn About REACH™ PSP
Clinical Trials
Learn about the details behind the IKEMA and ICARIA-MM trials and their efficacy results.
Adverse Reactions
Learn about the safety and tolerability profiles of SARCLISA® in the IKEMA and ICARIA-MM trials.
Dosing and Administration
Learn about SARCLISA®’s administration, dosing schedule, infusion rates and more.
Dosing and Administration